Sanofi (SNY, Financial) and Teva have announced that their Phase IIb RELIEVE UCCD study has met its primary endpoint. The research focuses on evaluating the efficacy, safety, pharmacokinetics, and tolerability of duvakitug for patients with moderate to severe ulcerative colitis (UC) and Crohn's disease (CD). Results indicate that patients treated with duvakitug experienced higher clinical remission rates compared to those on a placebo, highlighting its potential as a best-in-class therapy.
Duvakitug, developed by Teva, is a humanized IgG1-λ2 monoclonal antibody targeting TNF-like ligand 1A (TL1A). In October 2023, Sanofi entered a collaboration with Teva, involving a $500 million upfront payment and up to $1 billion in milestone payments for the drug's development and commercialization.
